Seoulin Bioscience Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
March 20, 2024 at 04:49 am EDT
Share
Seoulin Bioscience Co.,Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 31.96 million compared to KRW 91.49 million a year ago. Net loss was KRW 117.55 million compared to net income of KRW 10,158.81 million a year ago.
Basic loss per share from continuing operations was KRW 13.673 compared to basic earnings per share from continuing operations of KRW 1,182.711 a year ago. Diluted loss per share from continuing operations was KRW 13.673 compared to diluted earnings per share from continuing operations of KRW 811.5878 a year ago. Basic loss per share was KRW 13.673 compared to basic earnings per share of KRW 1,185.6409 a year ago.
Diluted loss per share was KRW 13.673 compared to diluted earnings per share of KRW 814.5177 a year ago.
Seoulin Bioscience Co., Ltd is a Korea-based company engaged in the developing and manufacturing of basic equipment for bio research. The Company mainly engages in research and development of reagents, such as deoxyribonucleic acid (DNA) chips, which are used for gene therapy, clinical diagnosis, organs transplantation and biopsy; stem cells, which are used for treatment of incurable diseases, Alzheimer disease and others, and next-generation biotechnology drugs. The company supplies its products under the brand name MyLab. It also imports bio research equipment from Thermo Fisher, Affymetrix, Sarstedt and others, and markets in the domestic market. In addition, the Company engages in the real estate rental business.
SEOULIN BIOSCIENCE CO.,LTD. 
